Supplementary Appendices eResults 1 eResults 1.1 Sub-analysis eResults 1.2 Deterministic analysis eFigures eFigure 1: Cost-effectiveness acceptability curves of each CVD risk algorithm, compared to no algorithm, when a CVD risk threshold of 20% was employed.
eResults 1 eResults 1.1 Sub-analysis
Head-to-head comparisons of the general and SMI-specific sub-type algorithms demonstrated the general lipid algorithm was more favourable than the SMI-specific lipid algorithm as the difference in costs between the SMI-specific algorithm and the general algorithm was greater. That is, the SMIspecific lipid algorithm had greater total costs than the general lipid algorithm. This, however, was not the case for the BMI versions, where the SMI-specific BMI algorithm performed better as the difference in costs between the SMI-specific algorithm and the general algorithm was less. The results were similar for both the 10% and 20% CVD risk thresholds, depicted in eFigure 2 and eFigure 3 respectively.
eResults 1.2 Deterministic analysis
The base case deterministic analysis (eTable 8a) represents the results when all input parameters are held at their mean value. In line with our PSA analysis, the base case deterministic analysis demonstrated greater cost-effectiveness with the SMI-specific BMI algorithm than other algorithms, with a NMB of £138,325,600 at a WTP per QALY gained of £20,000. Variation of individual input parameters produced different results for the most cost-effective algorithm. When compliance with statin therapy was reduced to 50%, the general lipid algorithm had the highest NMB. Altering the effectiveness of statin therapy by reducing its treatment effect resulted in the SMI-specific BMI algorithm performing better. Analyses where all costs were doubled resulted in the SMI-specific BMI algorithm with the highest NMB. This was also the case when only CVD risk algorithm costs were doubled. When only the costs of CVD risk management were doubled or only the costs of cardiovascular events were doubled, the SMI-specific BMI algorithm and general lipid algorithm were comparable. Reducing the utility associated with SMI to the utility associated with SMI and extra pyramidal symptoms (EPS) or to the utility associated with relapse, the general lipid algorithm was most cost-effective. In all analyses, the SMI-specific BMI algorithm or general lipid algorithm were superior to other CVD risk algorithms assessed. Differences in NMB between the SMI-specific BMI algorithm and general lipid algorithm were minimal. Results of the one-way deterministic analyses are reported in eTable 8. 203,107,979 (202,583,230 -203,632,729) 203,096,758 (202,572,212 -203,621,303) 203,061,735 (202,536,664 -203,586,807) 203,159,160 (202,637,681 -203,680,639) 202,972,522 (202,443,200 -203,501,845) 15 QALYs are the quality adjusted life years, NMB is the net monetary benefit, WTP is the willingness to pay, and discounted costs and QALYs reflect time-preference for current benefits over future ones. ,321,726 £138,286,240 £138,323,280 £138,325,660 £138,225,080 £30,000 WTP threshold £207,761,2215 £207,707,167 £207,763,778 £207,767,637 £207,610,6676 b) Deterministic analyses with 5,000 iterations when all costs are doubled. ,205,997 £207,206,198 £207,204,272 207,218,580 £207,090,933 QALYs are the quality adjusted life years, WTP is the willingness to pay, and discounted costs and QALYs reflect time-preference for current benefits over future ones. QALYs are the quality adjusted life years, WTP is the willingness to pay, and discounted costs and QALYs reflect time-preference for current benefits over future ones.
